Belumosudil Dosing for Chronic GVHD
The recommended dose of belumosudil for chronic graft-versus-host disease in patients ≥12 years old is 200 mg orally once daily, taken with food. 1
Standard Dosing
- Starting dose: 200 mg once daily with food
- Age requirement: ≥12 years old
- Food requirement: Must be taken with food (belumosudil exposure increases 2-fold with high-fat meals, which is the intended administration) 1
The FDA approval is based on the ROCKstar study, which demonstrated a 74-77% overall response rate in patients who had failed 2 or more prior lines of systemic therapy for chronic GVHD 2, 3. Both 200 mg once daily and 200 mg twice daily showed similar efficacy, but the once-daily regimen is the approved dose 1.
Dose Modifications with Drug Interactions
Strong CYP3A4 Inducers
Increase belumosudil to 200 mg twice daily (400 mg/day total) when coadministered with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) 1, 4. These agents significantly decrease belumosudil exposure, potentially reducing efficacy.
Proton Pump Inhibitors (PPIs)
Increase belumosudil to 200 mg twice daily (400 mg/day total) when coadministered with PPIs (e.g., omeprazole, rabeprazole) 1, 4. PPIs substantially reduce belumosudil absorption due to its pH-dependent solubility.
Strong CYP3A4 Inhibitors
No dose adjustment needed with strong CYP3A4 inhibitors like itraconazole 1, 4. However, be aware that moderate inhibitors like isavuconazole may still affect exposure, and therapeutic drug monitoring may be considered in complex cases 5.
Hepatic Impairment Dosing
Avoid belumosudil in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment without liver GVHD 1. In severe hepatic impairment, belumosudil exposure increases 4.2-fold (total) and 16-fold (free drug), creating unacceptable toxicity risk.
- Mild hepatic impairment (Child-Pugh A): No dose adjustment needed 1
- Moderate/severe hepatic impairment: Avoid use unless hepatic impairment is due to liver GVHD itself 1
Renal Impairment
No dose adjustment needed for mild to moderate renal impairment 1. Belumosudil has not been studied in severe renal impairment; consider risks versus benefits before initiating treatment in this population.
Important Drug Interaction Warnings
Avoid coadministration with sensitive substrates of:
- UGT1A1 (e.g., irinotecan, raltegravir) - belumosudil inhibits UGT1A1 1, 6
- P-glycoprotein (e.g., dabigatran, digoxin) - 2-fold increase in substrate exposure 1, 6
- OATP1B1 (e.g., statins) - 4.6-fold increase in rosuvastatin exposure 1, 6
- BCRP (e.g., methotrexate) - 3.6-fold increase in substrate exposure 1, 6
If coadministration cannot be avoided, reduce the dose of these substrates according to their prescribing information 1.
Clinical Context
Belumosudil is FDA-approved specifically for chronic GVHD after failure of at least 2 prior lines of systemic therapy 1, 2. The NCCN guidelines from 2020 discuss multiple agents for steroid-refractory chronic GVHD including ruxolitinib, ibrutinib, rituximab, and ECP 7, but belumosudil represents a newer option with distinct mechanism (ROCK2 inhibition) that was not yet available when those guidelines were published.
Common pitfalls to avoid:
- Not taking with food (significantly reduces absorption)
- Failing to increase dose when adding PPIs or strong CYP3A4 inducers
- Using in moderate/severe hepatic impairment without liver GVHD
- Missing critical drug-drug interactions with narrow therapeutic index drugs
The median duration of response is approximately 54 weeks, with 44% of patients remaining on therapy for ≥1 year 3. Steroid-sparing effects are substantial, with 59-62% of patients achieving symptom reduction 3, 8.